Zymeworks Inc. (ZYME) Q3 2025 10-Q Quarterly Report
Zymeworks Inc. (ZYME) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Zymeworks Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New risk: European Commission granted conditional marketing authorization of Ziihera® in July 2025, contingent on ongoing Phase 3 trial results
- • Material update: FDA accelerated approval of Ziihera® in Nov 2024 requires confirmatory trial; failure may lead to market removal impacting royalties
- • Regulatory risk: NMPA conditional approval in May 2025 for zanidatamab depends on ongoing confirmatory clinical benefit verification
- • Operational risk: Discontinuation of ZW171 clinical program in Sep 2025 after dose escalation phase due to unfavorable benefit-risk profile
- • Financial risk: Dependence on milestone payments and royalties from Jazz’s zanidatamab commercialization; no other product revenue as of Sept 30, 2025
Get deeper insights on Zymeworks Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.